Literature DB >> 22387577

Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.

Meyer Michel Samama1, Genevieve Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Jean Luc Martinoli.   

Abstract

This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated in a field trial involving 21 laboratories. Each laboratory was provided with rivaroxaban calibrators and control plasma samples containing different concentrations of rivaroxaban, and PT reagents. The evaluation was carried out over 2 consecutive weeks using centrally provided and local PT reagents. A calibration curve was produced each day (for inter-run precision), and day-to-day precision was evaluated by testing 3 control plasma samples. A large interlaboratory variation (in seconds) was observed with local PT reagents. The results were less variable when expressed as rivaroxaban concentrations (ng/mL) or when central PT reagent was used (STA Neoplastine CI Plus). The widely available PT assay, in conjunction with rivaroxaban calibrators, may be useful for the measurement of peak plasma levels of rivaroxaban.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387577     DOI: 10.1177/1076029611426282

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  18 in total

Review 1.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

Review 2.  Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Authors:  Helen Mani; Alexander Kasper; Edelgard Lindhoff-Last
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

3.  Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.

Authors:  Hans-Ulrich Siegmund; Rolf Burghaus; Dagmar Kubitza; Katrin Coboeken
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 4.  Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 5.  Measurement and reversal of the direct oral anticoagulants.

Authors:  Bethany T Samuelson; Adam Cuker
Journal:  Blood Rev       Date:  2016-09-02       Impact factor: 8.250

6.  Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Authors:  Meyer Michel Samama; Céline Guinet; Léna Le Flem; Emmanuel Ninin; Jean-Marc Debue
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 7.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Authors:  Adam Cuker; Deborah M Siegal; Mark A Crowther; David A Garcia
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

8.  A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.

Authors:  Muzaffar Iqbal; Nasr Y Khalil; Faisal Imam; Md Khalid Anwer
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

9.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

10.  Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.

Authors:  Debnath Maji; Aman Opneja; Michael A Suster; Kara L Bane; Brigid M Wilson; Pedram Mohseni; Evi X Stavrou
Journal:  Thromb Haemost       Date:  2020-09-02       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.